bags USD 299 Million for genetic diseases
BridgeBio Pharma has received a USD299.2 million for its progress in genetic disease pipeline. This includes assets in preclinical and clinical development. Several therapeutic areas are being taken under the consideration of the pharma. Also, they aim at a broad range of indications like transthyretin amyloidosis (ATTR), pantothenate kinase-associated neurodegeneration (PKAN), Gorlin syndrome and frequent basal cell carcinomas, Netherton syndrome, molybdenum cofactor deficiency Type A, and FGFR, SHP-2, and K-RAS-driven cancers and others.
receives USD 20 Million for blood cancer CAR-T
The Beijing biotech, Immunochina has raised USD 20 million in third-round financing to accelerate its CAR-T development programs. The company announced the capital will be used in extending its manufacturing capacity as well as funding trials of its lead CAR-T IM19 for B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin’s lymphoma. Immunochina is aiming domestic market of China for becoming an international CAR-T player.
Pharmaceuticals raises USD 23 Million for oral HAE drug
Attune Pharmaceuticals receives USD 23 million in series B financing for its oral drug for hereditary angioedema (HAE). The company targets to provide an oral alternative to approved treatments. The financing comes after the company presented phase 1 data for ATN-249. In addition to progressing the HAE candidate, ATN-249, the funding will also bolster the development of Attune’s preclinical pipeline.
receives USD 23 million
to drug protein-misfolding diseases
Wren Therapeutics has raised USD 23 million. The British biotech will use the capital for the series A round to progress its research into drugs to treat protein-misfolding diseases such as Alzheimer’s. The biotech progresses a technology, which will be potentially applicable to a plethora of diseases that emerge from the misfolding and malfunction of proteins, including Alzheimer’s, Parkinson’s and Type 2 diabetes.
The post The Business Cocktail appeared first on DelveInsight Business Research.